Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Hemostemix Inc V.HEM

Alternate Symbol(s):  HMTXF

Healthcare Biotechnology
Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.


TSXV:HEM - Post by User

Hemostemix Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by barmac6on Oct 26, 2011 8:25am
220 Views
Post# 19181894

Q3 2011 results Nov. 2

Q3 2011 results Nov. 2

Hemisphere GPS Inc (C-HEM) - News Release

Hemisphere GPS to release Q3 2011 results Nov. 2, call

2011-10-26 08:14 ET - News Release
Shares issued 60,824,409
HEM Close 2011-10-25 C$ 0.62

Mr. Cory Pala reports

HEMISPHERE GPS ISSUES Q3 CONFERENCE CALL NOTICE

Hemisphere GPS Inc. will release financial results prior to the open of trading on the Toronto Stock Exchange on Wednesday, Nov. 2, 2011. A conference call and webcast for shareholders, analysts and other members of the investment community has been scheduled the same day at 11 a.m. Eastern Time (9 a.m. Mountain Time) to discuss the financial results and provide an update on operations.

To participate in the conference call, please dial 1-647-427-7450 or 1-888-231-8191 approximately 10 minutes before the conference call. Please note that a live webcast of the call will be available on the Hemisphere GPS website. The webcast will be archived there for later review.

A recording of the call will be available through Nov. 11. Please dial 1-416-849-0833 or 1-855-859-2056 and enter password 22507147 to listen to the rebroadcast.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities